

Global Cancer Microbiome Market Report and Forecast 2024-2032

Market Report | 2023-09-22 | 140 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$2999.00
- Five User License \$3999.00
- Corporate License \$5999.00

Report description:

Global Cancer Microbiome Market Report and Forecast 2024-2032

Global Cancer Microbiome Market Outlook

The global cancer microbiome market size was valued at USD 267.1 million in 2023, driven by the increasing popularity of personalized medicine across the globe. The market size is anticipated to grow at a CAGR of 19.9% during the forecast period of 2024-2032 to achieve a value of USD 1,368.1 million by 2032.

Cancer Microbiome: Introduction

The cancer microbiome, in this context, typically refers to the microorganisms that may exist within the tumour microenvironment or in close proximity to cancer cells. Researchers have been exploring whether these microorganisms play a role in cancer development, progression, or treatment response. The composition of the microbiome within and around cancerous tissues can be highly heterogeneous, meaning it varies from person to person and even within different types of cancer. This complexity makes it challenging to pinpoint specific microbial signatures associated with cancer.

Scientists have been investigating the potential links between the cancer microbiome and various aspects of cancer, including inflammation, immune response, tumour growth, and treatment outcomes. Research in this field is ongoing and aims to better understand the role of microorganisms in cancer.

Key Trends in the Global Cancer Microbiome Market

Here are some potential trends that could influence the cancer microbiome market:

- ☐ Increased Research Activity: Research on the cancer microbiome was expected to continue growing. Advances in sequencing technologies and analytical tools have made it easier to characterize the microbiota associated with cancer, leading to a deeper understanding of its role.
- ☐ Diagnostic Biomarkers: Identification of specific microbial signatures associated with different types of cancer could lead to the development of diagnostic biomarkers. These biomarkers might help in early cancer detection and risk assessment, potentially creating a market for diagnostic tests related to the cancer microbiome.
- ☐ Immunotherapy Enhancement: Research into the interaction between the microbiome and the immune system has shown that certain microorganisms can influence the response to cancer immunotherapy. Companies may explore the development of

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

microbiome-based therapies or interventions to enhance the effectiveness of immunotherapies.

- Personalized Medicine: Just as the field of personalized medicine has been growing, understanding the individual's unique cancer microbiome profile could lead to personalized treatment approaches. Companies might develop therapies or interventions tailored to a patient's specific microbiome composition.

- Therapeutic Interventions: Some companies and researchers may explore microbiome-based therapeutic interventions for cancer. These could include the use of probiotics, prebiotics, fecal microbiota transplantation (FMT), or other approaches to manipulate the microbiome to influence cancer outcomes.

- Regulatory and Safety Considerations: As microbiome-based therapies and diagnostics are developed, regulatory agencies will play a crucial role in establishing safety and efficacy standards. Compliance with regulatory requirements will be essential for market entry.

Global Cancer Microbiome Market Segmentations

The market can be categorized into type, end user, and region.

Market Breakup by Type

- Products

- Services

Market Breakup by End User

- Hospitals

- Diagnostic Labs

Market Breakup by Region

- North America

- Europe

- Asia Pacific

- Latin America

- Middle East and Africa

Global Cancer Microbiome Market Overview

Here are some potential market drivers for the cancer microbiome market:

- Advancements in Research: Ongoing research into the role of the microbiome in cancer was a significant driver. As scientific understanding of the interactions between microorganisms and cancer cells improved, it created opportunities for the development of microbiome-based diagnostics and therapeutics.

- Diagnostic Biomarkers: Discovering specific microbial signatures or biomarkers associated with different types of cancer could drive the development of diagnostic tests. These tests might help with early cancer detection, risk assessment, and monitoring treatment responses, creating a market for microbiome-based diagnostics.

- Immunotherapy Enhancement: Understanding the microbiome's influence on the immune system and cancer immunotherapy response was a crucial driver. Companies aimed to develop microbiome-based interventions to enhance the effectiveness of cancer immunotherapies, such as checkpoint inhibitors.

- Personalized Medicine: The concept of personalized medicine, tailoring treatments to an individual's unique characteristics, including their microbiome profile, was gaining traction. The potential for microbiome-based personalized cancer therapies could drive market growth.

- Therapeutic Interventions: Research into microbiome-based therapeutic interventions for cancer was ongoing. Companies and researchers were exploring the use of probiotics, prebiotics, fecal microbiota transplantation (FMT), or microbiome-modulating drugs to improve cancer outcomes.

- Regulatory Considerations: Regulatory agencies were beginning to evaluate the safety and efficacy of microbiome-based therapies and diagnostics. Establishing clear regulatory pathways and standards for microbiome-related products could influence market development.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Cancer Microbiome Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- Novogene Corporation
- Psomagen
- PerkinElmer Genomics
- Illumina
- Thermo Fisher Scientific
- Viome
- Invivo Healthcare
- Zymo Research Corp
- Metabionics
- CD Genomics

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage - Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Cancer Microbiome Overview
- 3.1 Guidelines and stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Cancer Microbiome Epidemiology Analysis
- 5.1 Epidemiology Overview (2017-2032)
- 5.2 North America Cancer Microbiome Epidemiology (2017-2032)
- 5.3 Europe Cancer Microbiome Epidemiology (2017-2032)
- 5.4 Asia-Pacific Cancer Microbiome Epidemiology (2017-2032)
- 5.5 Latin America Cancer Microbiome Epidemiology (2017-2032)
- 5.6 Middle East & Africa Cancer Microbiome Epidemiology (2017-2032)
- 6 Global Cancer Microbiome Market Overview
- 6.1 Global Cancer Microbiome Market Historical Value (2017-2023)
- 6.2 Global Cancer Microbiome Market Forecast Value (2024-2032)
- 7 Global Cancer Microbiome Market Landscape
- 7.1 Cancer Microbiome: Developers Landscape

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.1.1Analysis by Year of Establishment
- 7.1.2Analysis by Company Size
- 7.1.3Analysis by Region
- 7.2Cancer Microbiome: Product Landscape
- 7.2.1Analysis by Type
- 7.2.2Analysis by End User
- 8Global Cancer Microbiome Market Dynamics
- 8.1Market Drivers and Constraints
- 8.2SWOT Analysis
- 8.3Porter's Five Forces Model
- 8.4Key Demand Indicators
- 8.5Key Price Indicators
- 8.6Industry Events, Initiatives, and Trends
- 8.7Value Chain Analysis
- 9Global Cancer Microbiome Market Segmentation
- 9.1Global Cancer Microbiome Market by Type
- 9.1.1Market Overview
- 9.1.2Products
- 9.1.3Services
- 9.2Global Cancer Microbiome Market by End User
- 9.2.1Market Overview
- 9.2.2Hospitals
- 9.2.3Diagnostic Labs
- 9.3Global Cancer Microbiome Market by Region
- 9.3.1Market Overview
- 9.3.2North America
- 9.3.3Europe
- 9.3.4Asia Pacific
- 9.3.5Latin America
- 9.3.6Middle East and Africa
- 10North America Cancer Microbiome Market
- 10.1Market Share by Country
- 10.2United States of America
- 10.3Canada
- 11Europe Cancer Microbiome Market
- 11.1Market Share by Country
- 11.2United Kingdom
- 11.3Germany
- 11.4France
- 11.5Italy
- 11.6Others
- 12Asia Pacific Cancer Microbiome Market
- 12.1Market Share by Country
- 12.2China
- 12.3Japan
- 12.4India
- 12.5ASEAN

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.6Australia
- 12.7Others
- 13Latin America Cancer Microbiome Market
 - 13.1Market Share by Country
 - 13.2Brazil
 - 13.3Argentina
 - 13.4Mexico
 - 13.5Others
- 14Middle East and Africa Cancer Microbiome Market
 - 14.1Market Share by Country
 - 14.2Saudi Arabia
 - 14.3United Arab Emirates
 - 14.4Nigeria
 - 14.5South Africa
 - 14.6Others
- 15Regulatory Framework
 - 15.1Regulatory Overview
 - 15.1.1US FDA
 - 15.1.2EU EMA
 - 15.1.3INDIA CDSCO
 - 15.1.4JAPAN PMDA
 - 15.1.5Others
- 16Patent Analysis
 - 16.1Analysis by Type of Patent
 - 16.2Analysis by Publication year
 - 16.3Analysis by Issuing Authority
 - 16.4Analysis by Patent Age
 - 16.5Analysis by CPC Analysis
 - 16.6Analysis by Patent Valuation
 - 16.7Analysis by Key Players
- 17Grants Analysis
 - 17.1Analysis by year
 - 17.2Analysis by Amount Awarded
 - 17.3Analysis by Issuing Authority
 - 17.4Analysis by Grant Application
 - 17.5Analysis by Funding Institute
 - 17.6Analysis by NIH Departments
 - 17.7Analysis by Recipient Organization
- 18Clinical Trials Analysis
 - 18.1 Analysis by Trial Registration Year
 - 18.2Analysis by Trial Status
 - 18.3Analysis by Trial Phase
 - 18.4Analysis by Therapeutic Area
 - 18.5Analysis by Geography
- 19Funding and Investment Analysis
 - 19.1Analysis by Funding Instances
 - 19.2Analysis by Type of Funding

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 19.3Analysis by Funding Amount
- 19.4Analysis by Leading Players
- 19.5Analysis by Leading Investors
- 19.6Analysis by Geography
- 20Partnership and Collaborations Analysis
- 20.1Analysis by Partnership Instances
- 20.2Analysis by Type of Partnership
- 20.3Analysis by Leading Players
- 20.4Analysis by Geography
- 21Supplier Landscape
- 21.1Novogene Corporation
 - 21.1.1Financial Analysis
 - 21.1.2Product Portfolio
 - 21.1.3Demographic Reach and Achievements
 - 21.1.4Mergers and Acquisitions
 - 21.1.5Certifications
- 21.2Psomagen
 - 21.2.1Financial Analysis
 - 21.2.2Product Portfolio
 - 21.2.3Demographic Reach and Achievements
 - 21.2.4Mergers and Acquisitions
 - 21.2.5Certifications
- 21.3PerkinElmer Genomics
 - 21.3.1Financial Analysis
 - 21.3.2Product Portfolio
 - 21.3.3Demographic Reach and Achievements
 - 21.3.4Mergers and Acquisitions
 - 21.3.5Certifications
- 21.4Illumina
 - 21.4.1Financial Analysis
 - 21.4.2Product Portfolio
 - 21.4.3Demographic Reach and Achievements
 - 21.4.4Mergers and Acquisitions
 - 21.4.5Certifications
- 21.5Thermo Fisher Scientific
 - 21.5.1Financial Analysis
 - 21.5.2Product Portfolio
 - 21.5.3Demographic Reach and Achievements
 - 21.5.4Mergers and Acquisitions
 - 21.5.5Certifications
- 21.6Viome
 - 21.6.1Financial Analysis
 - 21.6.2Product Portfolio
 - 21.6.3Demographic Reach and Achievements
 - 21.6.4Mergers and Acquisitions
 - 21.6.5Certifications
- 21.7Invivo Healthcare

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 21.7.1Financial Analysis
- 21.7.2Product Portfolio
- 21.7.3Demographic Reach and Achievements
- 21.7.4Mergers and Acquisitions
- 21.7.5Certifications
- 21.8Zymo Research Corp
- 21.8.1Financial Analysis
- 21.8.2Product Portfolio
- 21.8.3Demographic Reach and Achievements
- 21.8.4Mergers and Acquisitions
- 21.8.5Certifications
- 21.9Metabionics
- 21.9.1Financial Analysis
- 21.9.2Product Portfolio
- 21.9.3Demographic Reach and Achievements
- 21.9.4Mergers and Acquisitions
- 21.9.5Certifications
- 21.10CD Genomics
- 21.10.1Financial Analysis
- 21.10.2Product Portfolio
- 21.10.3Demographic Reach and Achievements
- 21.10.4Mergers and Acquisitions
- 21.10.5Certifications
- 22Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23Company Competitiveness Analysis (Additional Insight)
- 23.1Very Small Companies
- 23.2Small Companies
- 23.3Mid-Sized Companies
- 23.4Large Companies
- 23.5Very Large Companies
- 24Payment Methods (Additional Insight)
- 24.1Government Funded
- 24.2Private Insurance
- 24.3Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Cancer Microbiome Market Report and Forecast 2024-2032

Market Report | 2023-09-22 | 140 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$2999.00
	Five User License	\$3999.00
	Corporate License	\$5999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-05"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com